

The specification is also amended to introduce reference to SEQ ID NO:40. In the original application, SEQ ID NO:40 was not assigned to the sequence  $X_1X_2X_3X_4X_5X_6$  in claim 15 on page 34. The amendment assigns the sequence identifier SEQ ID NO:40 to this peptide. No new matter has been introduced by this amendment.

The amendment also corrects typographical errors in claim 15 as filed. The amino acid designation of  $X_2$  in claim 15 was originally disclosed as " $X_2$  is L, Q, F, or L;" and has been amended to recite " $X_2$  is L, Q, or F", to correspond with the description present in the specification. Also in claim 15, the amino acid designation of  $X_6$  was originally disclosed as " $X_6$  is P, A, F, K or A." and has been amended to recite " $X_6$  is P, A, F, or K." to correspond with the description present in the specification. This amendment to claim 15 renders the claim grammatically correct without changing its meaning. No new matter has been introduced by this amendment.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

A response to the Notice is due October 28, 2001, which falls on a Sunday. Therefore, this response is due or before Monday, October 29, 2001. Applicants believe that no fee is due with this submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 18242-507 (VI-7).

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

*For:* Ivor R. Elrifi, Reg. No. 45,409  
Ivor R. Elrifi, Reg. No.: 39,529  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: October 29, 2001

**Version with markings to show changes made**

**In the Claims:**

15. The peptide ligand of claim 7, wherein said peptide ligand includes the amino acid sequence  $X_1X_2X_3X_4X_5X_6$  (SEQ ID NO:40), provided that

$X_1$  is L, W, or I;

$X_2$  is L, Q, or F [, or L];

$X_3$  is I, Y, V, F, or L;

$X_4$  is W or V;

$X_5$  is I; and

$X_6$  is P, A, F, or K [, or A].

TRA 1587255v1